Dr Tony Oosterveen, Senior Scientist | Dr Zoe Nilsson, Global Product Marketing Manager | Ben Newman, Scientist
Watch this video to learn about the exciting first product from bit.bio’s new ioDisease Model portfolio, ioGlutamatergic Neurons HTT50CAG/WT for Huntington’s disease research and drug discovery.
In this video, you will learn about the development of the human iPSC-derived glutamatergic neurons with a 50 CAG repeat expansion, the power of opti-ox powered disease models and the benefit of using genetically matched controls in the study of Huntington’s disease.
The bit.bio team offers insights into the industry-leading consistency and scalability of ioGlutamatergic Neurons HTT50CAG/WT and the potential impact the disease model has on Huntington's disease research and drug discovery.
Find out more about the characterisation of our Huntington’s disease model in the brochure here.